Vaishali Pharma share news, announcements and annual reports
NSE: VAISHALIPharmaceuticals & BiotechnologySmall Cap
Vaishali Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2017 · Issue price ₹40
Last close ₹6.82down ₹0.28 (3.94%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹7.10.
28 Oct: open ₹6.92, high ₹7.33, low ₹6.73
52-week range of traded prices to 28 Oct 2026
₹4.75Low, 30 Mar 2026₹11.15High, 28 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹92 Cr2,938th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.33
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 6.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,69,65756.1% delivered
Vaishali Pharma disputes and clarifications
18 filed, newest first.
Jun 2026
24 Jun · Legal
Exchange has sought clarification from Vaishali Pharma Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated Statement of Cash Flow not submitted The response of the Company is awaited.
Apr 2026
22 Apr · Legal
The exchange asked on 21 Apr 2026
Feb 2026
Jan 2026
13 Jan · Legal
Exchange has sought clarification from Vaishali Pharma Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jan 2025
31 Jan · Legal
Exchange has sought clarification from Vaishali Pharma Limited with respect to announcement dated 28-Jan-2025, regarding " Vaishali Pharma Limited has informed the Exchange regarding Appointment of Mr BhaveshKumar Upadhyay as Independent Director of the company w.e.f. January 28, 2025.". On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the Company is awaited.
Jun 2023
5 Jun · Legal
Exchange has sought clarification from Vaishali Pharma Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Feb 2023
21 Feb · Legal
The exchange asked on 21 Feb 2023
Nov 2022
23 Nov · Legal
The exchange asked on 22 Nov 2022
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Mar 2022
4 Mar · Legal
The exchange asked on 3 Mar 2022
Feb 2022
14 Feb · Legal
The exchange asked on 11 Feb 2022
Jul 2021
12 Jul · Legal
Exchange has sought clarification from Vaishali Pharma Limited with respect to announcement dated 10-Jul-2021, regarding Appointment of Mr Pratik Vikram Jakhelia. On basis of above the Company is required to provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.
Nov 2020
Dec 2019
13 Dec · Legal
Exchange has sought clarification from Vaishali Pharma Limited with respect to announcement dated 11-Dec-2019 regarding Board meeting held on December 11 2019 for appointment of Company Secretary". On basis of above the Company is required to clarify following: 1. Brief profile in case of appointment of Mrs. Pooja Garg. The response of the Company is awaited.
Jun 2018
6 Jun · Legal
Exchange has sought clarification from Vaishali Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.